Determining the effect of ketamine on the rate of depressive, anxiety and PTSD disorders after discharge from ICU

Comparison of the effect of ketamine and midazolam with morphine on the rate of depressive and anxiety disorders and PTSD in mechanically ventilated patients in the intensive care unit

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170413033408N5

Enrollment

Registered

2021-02-07

Start date

2021-02-19

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: depressive and anxiety disorders. Condition 2: Post traumatic stress disorder. Mixed anxiety and depressive disorder Post-traumatic stress disorder (PTSD)

Interventions

Intervention 1: Intervention group: The ketamine group is infused at a dose of 0.5 mg / kg for 15 minutes, followed by an intravenous infusion of 0.5 µ/kg/h. Intervention 2: Control group: Midazolam a

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: All patients should be mechanically ventilated in the ICU for at least 48 hours. Measurement Acute Physiology and Chronic Health Evaluation II Upon entering the ICU Age range 18-60 years

Exclusion criteria

Exclusion criteria: Patients due to drug poisoning Patients due to suicide Patients after cardiopulmonary resuscitation Post CPR Patients with a history of brain dementia and Alzheimer's Patients with extensive cerebral hemorrhage Patients with GCS = 3 at the time of admission to the ICU Patients with a history of taking neurological drugs

Design outcomes

Primary

Measure	Time frame
The rate of depressive disorders. Timepoint: Mean score of depressive disorders during two weeks, two months and six months after discharge. Method of measurement: The first interview was conducted two weeks later and the next interview was conducted two months later and six months later by telephone using Beck Depression questionnaire.;Anxiety Disorders. Timepoint: Mean score of anxiety disorders during two weeks, two months and six months after discharge. Method of measurement: The first interview was conducted two weeks later and the next interview was conducted two months later and six months later by telephone using the Beck Anxiety questionnaire.;PTSD Disorders. Timepoint: Mean score of PTSD disorders during two weeks, two months and six months after discharge. Method of measurement: The first interview was conducted two weeks later and the next interview two months later and six months later by telephone using the PCI questionnaire.	—

Measure

Time frame

The rate of depressive disorders. Timepoint: Mean score of depressive disorders during two weeks, two months and six months after discharge. Method of measurement: The first interview was conducted two weeks later and the next interview was conducted two months later and six months later by telephone using Beck Depression questionnaire.;Anxiety Disorders. Timepoint: Mean score of anxiety disorders during two weeks, two months and six months after discharge. Method of measurement: The first interview was conducted two weeks later and the next interview was conducted two months later and six months later by telephone using the Beck Anxiety questionnaire.;PTSD Disorders. Timepoint: Mean score of PTSD disorders during two weeks, two months and six months after discharge. Method of measurement: The first interview was conducted two weeks later and the next interview two months later and six months later by telephone using the PCI questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactdr Babak Mojaver Aghilli

Gorgan University of Medical Sciences

drbabaka35@gmail.com+98 17 3115 3566

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026